Allopurinol, uric acid, and oxidative stress in cardiorenal disease

作者：Riegersperger Markus^*; Covic Adrian; Goldsmith David

来源：International Urology and Nephrology, 2011, 43(2): 441-449.

DOI：10.1007/s11255-011-9929-6

• Allopurinol
• Arterial hypertension
• Cardiovascular disease
• Chronic kidney disease
• Diabetes mellitus
• Heart disease
• Hyperuricemia
• Oxidative stress
• Uric acid
• Xanthine oxidase

In humans, the hepatic end product of purine metabolism is uric acid. Serum uric acid levels physiologically and gradually rise during human lifetime. Hyperuricemia also arises from excess dietary purine or ethanol intake, decreased renal excretion of uric acid, tumor lysis in lymphoma, leukemia or solid tumors, and sometimes pharmacotherapy. The definition of hyperuricemia is currently arbitrary. Hyperuricemia is associated with chronic kidney disease, arterial hypertension, coronary artery and heart disease, cerebrovascular disease and diabetes mellitus. Xanthine oxidase, a hepatic enzyme, catalyzes the production of uric acid, nitric oxide, and reactive oxygen species, which potentially damage deoxyribonucleic acid, ribonucleic acid and proteins, inactivate enzymes, oxidize amino acids and convert poly-unsaturated fatty acids to lipids. This is believed to contribute to atherosclerosis, endothelial dysfunction, renovascular hypertension, and cardiovascular disease. Xanthine oxidase inhibition efficiently blocks uric acid generation, and this improves glomerular filtration rates, systemic blood pressure, and cerebro-cardiovascular outcomes. Here, data from animal, in vivo, retro- and prospective, and interventional studies are reported.

• 出版日期2011-6